Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures

NEW YORK, Feb. 7, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures

http://www.reportlinker.com/p0887611/Pharmaceutical-Pricing-and-Reimbursement-in-China---Series-of-Mandated-Price-Cuts-Not-Effective-in-Stemming-Healthcare-Expenditures.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Managed_care

Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures

Summary GBI Research, the leading business intelligence provider, has released its latest research "Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures". The report provides a comprehensive overview of the healthcare system, and pricing and reimbursement process in China with key data, information and analysis of pricing and reimbursement steps. The report closely scrutinizes major changes in the pharmaceuticals-related pricing and reimbursement scene in China, due to the implementation of the 2009 Healthcare Reform.

Pricing and reimbursement is of paramount importance in China because of the rapidly rising expenditure on drugs. These issues become more acute because of the large population in China, and its associated effects on expenditure on drugs. Although the rapidly growing population and shift towards urbanization offer a large market for drug manufacturers, the market is tempered by the pricing and reimbursement system in China. Challenges faced by companies entering the Chinese pharmaceutical market include government price controls, extensive retail mark-ups, and wide regional variations in insurance.

Pharmaceutical price and pharmaceutical quantity are major factors contributing to healthcare expenditure. The control of retail prices alone is not effective in containing healthcare expenditures; it is also essential to prescribe efficient pharmaceutical utilization. Efficient pharmaceutical utilization is achieved by the use of appropriate reimbursement mechanisms, and a prospective payment system. This cost-driving reimbursement mechanism is incompatible with the goal of containing health-care costs. The reform of the reimbursement mechanism therefore plays a vital role in the changing incentives to the providers. The new reimbursement mechanism provides incentives to healthcare professionals, encouraging efficiency and cost savings when using all health resources, including drugs. The new reimbursement mechanism is an effective countermeasure for the Chinese healthcare system, which is plagued by over-prescription, abuse of quality technology services and cost shifting. A large part of the pharmaceutical market growth is propelled by the expansion of the public sector health insurance coverage, which also includes a greater reimbursement of drugs.

Scope - Detailed study of the healthcare scenario in the China

- Analysis of the pricing and reimbursement mechanisms in China

- Key changes that follow on from the implementation of new Healthcare Reform 2009 within the pricing and reimbursement system

- Details about government bodies which regulate different processes of pricing and reimbursement in China

- Insight into various reimbursement programs in China

Reasons to buy - Build an understanding of the pharmaceuticals-related key pricing and reimbursement mechanisms in China

- Optimize your investment through identification and understanding of the changes in the pharmaceutical regulatory mechanisms in China

- Gain knowledge regarding the regulatory bodies who undertake different processes of price registration

- Develop effective business strategies related to new drug launches through the analytical insight gained from key trends in the pricing and reimbursement scene in China

- Negotiate better with the government agencies to maximize reimbursement on the drugs by understanding the mechanism

Table of Contents

1 Table of Contents1 Table of Contents 51.1 List of Tables 61.2 List of Figures 72 Pricing and Reimbursement in China - Introduction 83 Healthcare System in China - Overview 93.1 Introduction 93.1.1 Sizable Population and Increase in Life Expectancy 103.2 Socio-Economic and Demographic Trends Affecting the Healthcare Sector 123.2.1 Shift in Demographics 123.2.2 Rise in Personal Disposable Income 133.2.3 Rise in Lifestyle Diseases 143.3 Healthcare Expenditure 153.3.1 Healthcare Expenditure Comparatively Low 173.3.2 Healthcare System in China: A Backdrop 183.3.3 PEST Analysis 193.4 Healthcare Regulation 213.4.1 Ministry of Health 233.4.2 The National Development and Reform Commission (NDRC) 233.4.3 Chinese Center for Disease Control and Prevention (China CDC) 233.4.4 The Ministry of Finance (MoF) 233.4.5 Ministry of Labor and Social Security (MoLSS) 243.5 Healthcare Reforms 2009-2011 Aimed to Offer Better Access, Efficiency and Quality 243.6 Effectiveness of Healthcare Reform 2009–2011 273.6.1 Pillars of China's Health Reform: EMS and Reform of Publicly Funded Hospitals 273.7 Evolving Trends in the Healthcare System in China 283.7.1 Increase in Taiwanese Investment in Hospitals in China 283.7.2 Hospital Advertising 284 Pricing and Reimbursement in China - Overview 294.1 Pharmaceuticals in Healthcare Systems in China 294.1.1 OTC Drug Market in China 295 Pricing and Reimbursement in China - Pricing 315.1 Drug Pricing Mechanism 315.1.1 Pricing of List A Drugs 325.1.2 Pricing of List B Drugs 325.1.3 Principles for Government Pricing: 335.1.4 NDRC Drug Pricing: Criteria for Evaluation 345.1.5 Objectives for Drug Price Regulation in China 355.2 National Essential Medicines List (NEML) 355.2.1 National Essential Medicines List - 2009 365.2.2 Essential Drugs List (2000 - 2009) 375.2.3 NEML 2009 Continues to Focus on Affordability and Accessibility 385.3 Drug Regulation Pattern 395.3.1 Key Reasons for High Drug Price in China 395.3.2 Differential Drug Pricing 395.3.3 Pricing Premiums 405.3.4 Foreign Drugs Exempt from Price Cuts 405.3.5 Drug Pricing Trends Closely Followed by R&D-Based Pharmaceutical Companies 405.4 Drug Registration Process 415.4.1 Classification of Drugs 415.4.2 New Drug Registration Process: 425.4.3 Negative Pricing Pressures Not Effective in Stemming Healthcare Expenditures 435.4.4 Challenges Facing Pricing and Reimbursement in China 456 Pricing and Reimbursement in China - Reimbursement Scenario 466.1 Health Insurance in China 466.1.1 Urban Health Insurance 476.1.2 Rural Health Insurance 476.1.3 Private Insurance 486.1.4 Private Insurance Sector is Thriving 496.1.5 Universal Health Insurance Coverage 496.2 Drug Reimbursement in China 506.2.1 NDRL Listing Implications 526.2.2 Role of Key Stakeholders in Approving Drugs for Reimbursement 526.2.3 Key Criteria for the Drug Reimbursement Selection Process 526.2.4 NDRL 2009 to Push Drug Sales in the Future 547 Appendix 557.1 Market Definitions 557.2 Abbreviations 557.3 Sources 567.4 Research Methodology 577.4.1 Healthcare System 577.4.2 Pharmaceutical Regulations 577.4.3 Pricing of Pharmaceutical Drugs 587.4.4 Reimbursement of Pharmaceutical Drugs 587.4.5 Pricing and Reimbursement in Major Therapy Areas 587.5 Contact Us 587.6 Disclaimer 58

List of Tables Table 1: Pricing and Reimbursement in China, Population Estimates and Projections, 2006-2015 10

Table 2: Pricing and Reimbursement in China, Life Expectancy Estimates and Projections 1970-2020 11

Table 3: Pricing and Reimbursement in China, Rise in Personal Disposable Income, ($), 2005-2013 13

Table 4: Pricing and Reimbursement in China, Top 10 Leading Causes of Death in Urban and Rural, 2009 14

Table 5: Pricing and Reimbursement in China, Estimated Public Health Spending as a % of GDP, 2006–2015 16

Table 6: Pricing and Reimbursement in China, Health Expenditure per Capita ($), 2006–2015 16

Table 7: Pricing and Reimbursement in China, BRIC and The US, Health Expenditure as a % of GDP ($), 2006–2010 17

Table 8: Pricing and Reimbursement in China, BRIC and The US, Health Expenditure per Capita ($), 2006–2010 17

Table 9: Pricing and Reimbursement in China, BRIC and The US, Public Health Expenditure as a % of Total Health Expenditure ($), 2006–2010 17

Table 10: Pricing and Reimbursement in China, BRIC and The US, Out-of-Pocket Health Expenditure as a % of Private Expenditure on Health, ($), 2006–2010 18

Table 11: Pricing and Reimbursement in China, Role of Organizations in Healthcare System, 2011 22

Table 12: Pricing and Reimbursement in China, China, Market Size by Category ($bn), 2003-2009 30

Table 13: Pricing and Reimbursement in China, Price Caps for Certain Essential Drugs, 2009 34

Table 14: Pricing and Reimbursement in China, National Essential Drugs List by Therapeutic Class, 2009 36

Table 15: Pricing and Reimbursement in China, National Essential Drugs List Comparison, 2004 vs. 2009 38

Table 16: Pricing and Reimbursement in China, New Drug Application Classes, 2011 41

Table 17: Pricing and Reimbursement in China, Abbreviated New Drug Applications Classes, 2011 41

Table 18: Pricing and Reimbursement in China, Price Cuts 2000-2011 44

Table 19: Pricing and Reimbursement in China, Basic Medical Insurance Coverage in Urban Population, ('0,000) 2000-2011 47

Table 20: Pricing and Reimbursement in China, Foreign Joint Stock Insurance Companies, 2010 48

Table 21: Pricing and Reimbursement in China, Foreign Joint Venture Insurance Companies, 2010 48

Table 22: Pricing and Reimbursement in China, Major Foreign Players in Insurance Sector, 2010 48

Table 23: Pricing and Reimbursement in China, National Drug Reimbursement List, 2009 53

List of Figures Figure 1: Pricing and Reimbursement in China, GDP Estimates and Projections, 2006-2015 9

Figure 2: Pricing and Reimbursement in China, Population Estimates and Projections, 2006-2015 10

Figure 3: Pricing and Reimbursement in China, Average Life Expectancy Estimates and Projections, 1970-2020 11

Figure 4: Pricing and Reimbursement in China, Population Aged 65 and Above, (% of Population), 2008-2040 12

Figure 5: Pricing and Reimbursement in China , Increase in Personal Disposable Income, ($), 2005-2013 13

Figure 6: Pricing and Reimbursement in China, National Healthcare Expenditure (% of GDP), 2010 15

Figure 7: Pricing and Reimbursement in China, Total Healthcare Spending, $bn, 2006–2015 15

Figure 8: Pricing and Reimbursement in China, Estimated Public Health Spending as a % of GDP, 2006–2015 16

Figure 9: Pricing and Reimbursement in China, PEST Analysis, 2011 19

Figure 10: Pricing and Reimbursement in China, Healthcare Regulation, 2011 21

Figure 11: Pricing and Reimbursement in China, Key Issues of Healthcare, 2009-2011 24

Figure 12: Pricing and Reimbursement in China, Budget Allocation in Healthcare Reforms, (%), 2009 26

Figure 13: Pricing and Reimbursement in China, Healthcare Reform, 2009 26

Figure 14: Pricing and Reimbursement in China, Pillars of Health Care Reform, 2009–2011 27

Figure 15: Pricing and Reimbursement in China, Pharmaceutical Market Ranking, 2009 vs. 2013 29

Figure 16: Pricing and Reimbursement in China, Measures Adopted to Control Pharmaceutical Expenditures, 2011 30

Figure 17: Pricing and Reimbursement in China, Drug Pricing Mechanism, 2011 32

Figure 18: Pricing and Reimbursement in China, NDRC Drug Pricing Principles, 2011 33

Figure 19: Pricing and Reimbursement in China, National Essential Drugs List by Therapeutic Class, 2009 36

Figure 20: Pricing and Reimbursement in China, National Essential Drugs List, 2000-2009 37

Figure 21: Pricing and Reimbursement in China, Drug Registration Flow Chart, 2011 42

Figure 22: Pricing and Reimbursement in China, Key Developments in Healthcare Insurance Sector, 1998-2011 46

Figure 23: Pricing and Reimbursement in China, Healthcare Insurance Coverage, 2006, 2009 and 2011 49

Figure 24: Pricing and Reimbursement in China, Healthcare Insurance, 2009-2011 50

Figure 25: Pricing and Reimbursement in China, National Drug Reimbursement List, 2009 vs. 2004 51

Figure 26: Pricing and Reimbursement in China, National Drug Reimbursement List by Therapeutic Class, 2009 53

To order this report:Managed_care Industry: Pharmaceutical Pricing and Reimbursement in China - Series of Mandated Price Cuts Not Effective in Stemming Healthcare Expenditures

Contact Clare: clare@reportlinker.com
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.